Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective
Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target...
Saved in:
| Published in | Immunity (Cambridge, Mass.) Vol. 53; no. 4; pp. 852 - 863.e7 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
13.10.2020
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs.
[Display omitted]
•Generation of seven human monoclonal antibodies to influenza B virus neuraminidase•Two antibodies, 1G05 and 2E01, are broadly cross-reactive•1G05 and 2E01 are potently protective against lethal Influenza B infection in mice•1G05 and 2E01 bind conserved residues in the Influenza B neuraminidase active site
Influenza B virus (IBV) infections cause severe disease. Madsen et al. develop and characterize human monoclonal antibodies that possess broad and potent capacities to inhibit IBV neuraminidase enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. |
|---|---|
| AbstractList | Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs.Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs. Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs. [Display omitted] •Generation of seven human monoclonal antibodies to influenza B virus neuraminidase•Two antibodies, 1G05 and 2E01, are broadly cross-reactive•1G05 and 2E01 are potently protective against lethal Influenza B infection in mice•1G05 and 2E01 bind conserved residues in the Influenza B neuraminidase active site Influenza B virus (IBV) infections cause severe disease. Madsen et al. develop and characterize human monoclonal antibodies that possess broad and potent capacities to inhibit IBV neuraminidase enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs. SummaryInfluenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved among IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs. Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target of broadly protective antibodies that recognize the NA active site of IAVs. However, similarly broadly protective antibodies against IBV NA have not been identified. Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an IBV-infected patient. Two mAbs displayed broad and potent capacity to inhibit IBV NA enzymatic activity, neutralize the virus in vitro , and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. These mAbs inserted long CDR-H3 loops into the NA active site, engaging residues highly conserved amongst IBV NAs. These mAbs provide a blueprint for the development of improved vaccines and therapeutics against IBVs. Influenza B virus (IBV) infections cause severe disease. Madsen et al. develop and characterize human monoclonal antibodies that possess broad and potent capacities to inhibit IBV neuraminidase enzymatic activity, neutralize the virus in vitro, and protect against lethal IBV infection in mice in prophylactic and therapeutic settings. |
| Author | Krammer, Florian Ellebedy, Ali H. Cox, Rebecca J. Alsoussi, Wafaa B. Tan, Jessica Madsen, Anders Mudd, Philip A. Strohmeier, Shirin Schmitz, Aaron J. Amor, Mostafa Mohammed, Bassem M. Simon, Viviana Fremont, Daved H. Dai, Ya-Nan McMahon, Meagan Lei, Tingting Turner, Jackson S. |
| AuthorAffiliation | 10 Lead contact 6 Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA 5 Department of Microbiology, Haukeland University Hospital, 5021 Bergen, Norway 9 Equal contribution 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA 8 The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA 1 Influenza Centre, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway 4 Division of Emergency Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA 2 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA 7 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA |
| AuthorAffiliation_xml | – name: 4 Division of Emergency Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA – name: 9 Equal contribution – name: 8 The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA – name: 1 Influenza Centre, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway – name: 3 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – name: 10 Lead contact – name: 6 Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA – name: 2 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – name: 5 Department of Microbiology, Haukeland University Hospital, 5021 Bergen, Norway – name: 7 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA |
| Author_xml | – sequence: 1 givenname: Anders orcidid: 0000-0002-0626-5443 surname: Madsen fullname: Madsen, Anders organization: Influenza Centre, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway – sequence: 2 givenname: Ya-Nan orcidid: 0000-0003-1618-3043 surname: Dai fullname: Dai, Ya-Nan organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 3 givenname: Meagan surname: McMahon fullname: McMahon, Meagan organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – sequence: 4 givenname: Aaron J. surname: Schmitz fullname: Schmitz, Aaron J. organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 5 givenname: Jackson S. surname: Turner fullname: Turner, Jackson S. organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 6 givenname: Jessica surname: Tan fullname: Tan, Jessica organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – sequence: 7 givenname: Tingting surname: Lei fullname: Lei, Tingting organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 8 givenname: Wafaa B. surname: Alsoussi fullname: Alsoussi, Wafaa B. organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 9 givenname: Shirin surname: Strohmeier fullname: Strohmeier, Shirin organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – sequence: 10 givenname: Mostafa surname: Amor fullname: Amor, Mostafa organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 11 givenname: Bassem M. surname: Mohammed fullname: Mohammed, Bassem M. organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 12 givenname: Philip A. orcidid: 0000-0002-3860-5473 surname: Mudd fullname: Mudd, Philip A. organization: Division of Emergency Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 13 givenname: Viviana surname: Simon fullname: Simon, Viviana organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – sequence: 14 givenname: Rebecca J. surname: Cox fullname: Cox, Rebecca J. organization: Influenza Centre, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway – sequence: 15 givenname: Daved H. surname: Fremont fullname: Fremont, Daved H. email: fremont@wustl.edu organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA – sequence: 16 givenname: Florian surname: Krammer fullname: Krammer, Florian email: florian.krammer@mssm.edu organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA – sequence: 17 givenname: Ali H. surname: Ellebedy fullname: Ellebedy, Ali H. email: ellebedy@wustl.edu organization: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32976769$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9v1DAQxS1URP_AN0AoEhcuCePEjhMOSNsKaKUKkCjckOW1J8usEru1k5XKpyfbXSroAU4z0vzmad68Y3bgg0fGnnMoOPD69bqgYZg8FSWUUEBTAJeP2BGHVuWCN3Cw7ZXIVc2rQ3ac0hqAC9nCE3ZYla2qVd0ese_n02B8tvAjLYMjTNmViSscya-yC9_1E_qfJjvNvlGcUvYRp2gG8uRMwmxhR9pg9oXGuY-YncZgXH-bfY5hxLvZU_a4M33CZ_t6wr6-f3d1dp5ffvpwcba4zK2UasyddVAueVfXXJYNCGtASIsOa6lAQNuJbilbLp2qFHfGlV2tVGuUEVUHyGV1wt7udK-n5YDOoh-j6fV1pMHEWx0M6b8nnn7oVdhoJVXZ8GoWeLUXiOFmwjTqgZLFvjcew5R0KURdK65UM6MvH6DrMEU_25spCUpKyduZevHnRfen_P78DIgdYGNIKWJ3j3DQ24D1Wu8C1tuANTQa7py-ebBmaTQjha0v6v-3vH8TzllsCKNOltDPn6Y4B6ZdoH8L_AJ6EsQ1 |
| CitedBy_id | crossref_primary_10_3389_fimmu_2021_786617 crossref_primary_10_3390_vaccines9040404 crossref_primary_10_1016_j_immuni_2023_07_004 crossref_primary_10_1016_j_bbadis_2025_167772 crossref_primary_10_1002_jmv_28106 crossref_primary_10_1111_nyas_14915 crossref_primary_10_1126_science_2020_5_53_twil crossref_primary_10_1016_j_coviro_2022_101207 crossref_primary_10_1128_jvi_01186_24 crossref_primary_10_1016_j_scitotenv_2024_177077 crossref_primary_10_1038_s41467_024_53301_6 crossref_primary_10_1128_jvi_01646_22 crossref_primary_10_1016_j_antiviral_2023_105785 crossref_primary_10_1128_JVI_01421_21 crossref_primary_10_3389_fimmu_2022_944907 crossref_primary_10_1128_msphere_00927_21 crossref_primary_10_1016_j_virol_2022_02_004 crossref_primary_10_1038_s41586_023_06136_y crossref_primary_10_3390_molecules27051640 crossref_primary_10_1080_14760584_2021_1964961 crossref_primary_10_1111_irv_13276 crossref_primary_10_3390_v13060973 crossref_primary_10_1146_annurev_immunol_042718_041309 crossref_primary_10_1016_j_immuni_2024_02_003 crossref_primary_10_1016_j_vaccine_2025_126994 crossref_primary_10_3390_v13091710 crossref_primary_10_1016_j_jaut_2021_102596 crossref_primary_10_1080_21645515_2024_2421096 crossref_primary_10_1071_MA21033 crossref_primary_10_1126_sciimmunol_abf4907 crossref_primary_10_3390_vaccines9080846 crossref_primary_10_1016_j_immuni_2023_10_005 crossref_primary_10_1038_s41423_020_00617_0 crossref_primary_10_1016_j_indcrop_2022_114524 crossref_primary_10_1038_s41467_022_29416_z crossref_primary_10_1016_j_heliyon_2024_e37661 crossref_primary_10_1128_mBio_02241_21 crossref_primary_10_1016_j_immuni_2024_05_002 crossref_primary_10_1016_j_it_2023_11_001 crossref_primary_10_1038_s41467_022_32149_8 crossref_primary_10_3390_vaccines9020125 crossref_primary_10_1080_14760584_2023_2290691 crossref_primary_10_3390_v13101893 crossref_primary_10_3390_v15010200 crossref_primary_10_3390_v16010077 crossref_primary_10_1038_s41467_021_26409_2 crossref_primary_10_1371_journal_pone_0280825 crossref_primary_10_17776_csj_1375105 crossref_primary_10_1038_s41467_022_34521_0 crossref_primary_10_1038_s41541_022_00486_w |
| Cites_doi | 10.1021/jm00031a011 10.1021/bi00391a020 10.1073/pnas.1916585116 10.1107/S0907444909052925 10.1002/pro.3235 10.1016/j.chom.2017.07.013 10.1016/j.ultramic.2013.06.004 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N 10.1016/j.chom.2019.10.003 10.1073/pnas.1906613117 10.1016/j.jsb.2015.11.003 10.1038/s41594-018-0025-9 10.1111/j.1432-1033.1992.tb17055.x 10.1056/NEJMp1714916 10.7554/eLife.42166 10.1016/j.coi.2018.03.025 10.1038/nmeth.2727 10.1128/mBio.00560-19 10.1128/mBio.00066-19 10.1038/s41564-017-0011-8 10.1038/ni.3533 10.1016/j.jim.2016.09.001 10.1038/nm.3443 10.1086/505868 10.1128/mBio.02332-17 10.3389/fimmu.2012.00053 10.1128/mBio.02556-14 10.2105/AJPH.2012.301137 10.1086/509925 10.1126/science.aay0678 10.1084/jem.20101352 10.3201/eid2510.190607 10.1038/s41564-019-0392-y 10.1093/nar/gkn316 10.1093/molbev/mst197 10.1016/j.antiviral.2013.08.023 10.1086/314440 10.1371/journal.ppat.1006749 10.1016/j.cell.2018.03.030 10.1007/978-1-62703-646-7_6 10.1016/j.immuni.2017.09.007 10.1128/JVI.00959-08 10.1086/500465 10.1016/j.vaccine.2009.08.038 10.1107/S0907444904019158 10.1038/s41426-018-0115-0 10.1107/S0907444909042073 10.1038/s42003-019-0437-z 10.1038/nri3285 10.1038/nmeth.4193 10.1620/tjem.214.113 10.1016/0042-6822(90)90186-U 10.1093/infdis/jiy103 10.1016/j.coi.2018.04.002 10.1016/j.chom.2019.10.002 10.1038/nprot.2009.3 10.1002/jcc.20084 10.1016/0969-2126(93)90005-2 10.1038/s41577-019-0143-6 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Inc. Copyright © 2020 Elsevier Inc. All rights reserved. 2020. Elsevier Inc. |
| Copyright_xml | – notice: 2020 Elsevier Inc. – notice: Copyright © 2020 Elsevier Inc. All rights reserved. – notice: 2020. Elsevier Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 8FD C1K FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 5PM |
| DOI | 10.1016/j.immuni.2020.08.015 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Chemoreception Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1097-4180 |
| EndPage | 863.e7 |
| ExternalDocumentID | PMC7572813 32976769 10_1016_j_immuni_2020_08_015 S1074761320303721 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | New York Thailand United States--US Phuket Thailand |
| GeographicLocations_xml | – name: New York – name: Phuket Thailand – name: Thailand – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: HHSN272201400008C – fundername: NIAID NIH HHS grantid: HHSN272201700060C – fundername: NIAID NIH HHS grantid: HHSN272201400006C – fundername: NIAID NIH HHS grantid: R01 AI117287 – fundername: NCATS NIH HHS grantid: UL1 TR002345 – fundername: NIAID NIH HHS grantid: 75N93019C00051 – fundername: NIAID NIH HHS grantid: R21 AI139813 – fundername: NIAID NIH HHS grantid: U01 AI141990 – fundername: NIAID NIH HHS grantid: R01 AI128821 – fundername: NCI NIH HHS grantid: T32 CA009547 |
| GroupedDBID | --- --K -DZ 0R~ 1RT 1~5 2WC 4.4 457 4G. 53G 5GY 62- 7-5 8C1 8FE 8FH AACTN AAEDW AAFTH AAIAV AAKRW AALRI AAUCE AAVLU AAXUO ABMAC ABMWF ABOCM ABVKL ACGFO ACGFS ACIWK ACPRK ADBBV ADEZE ADFRT ADJPV AEFWE AENEX AEXQZ AFRAH AFTJW AGGSO AGKMS AHMBA AITUG ALKID ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL BBNVY BENPR BKEYQ BPHCQ BVXVI C45 CS3 DIK DU5 E3Z EBS EJD F5P FCP FDB FIRID IH2 IHE IXB J1W JIG LK8 LX5 M2O M3Z M41 N9A O-L O9- OK1 OVD P2P PQQKQ PROAC RCE ROL RPZ SCP SES SSZ TEORI TR2 WQ6 ZA5 .55 .GJ 29I 5VS AAEDT AAIKJ AAMRU AAQFI AAQXK AAYWO AAYXX ABDGV ABJNI ABWVN ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN AEUPX AFPUW AGCQF AGHFR AGQPQ AHHHB AIGII AKAPO AKBMS AKRWK AKYEP APXCP CITATION FEDTE FGOYB G-2 HVGLF HZ~ OHT OZT R2- RIG UHS X7M Y6R ZGI CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7T5 7T7 7TK 7TM 7U9 8FD C1K EFKBS FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c557t-dcd02b1f66152804ca045cede6570409f4fb5915d7371dad2f6779a7a43f0e153 |
| IEDL.DBID | IXB |
| ISSN | 1074-7613 1097-4180 |
| IngestDate | Thu Aug 21 14:13:12 EDT 2025 Thu Jul 10 23:34:39 EDT 2025 Fri Jul 25 11:12:24 EDT 2025 Thu Apr 03 07:02:35 EDT 2025 Thu Apr 24 23:12:50 EDT 2025 Tue Jul 01 01:58:43 EDT 2025 Fri Feb 23 02:44:47 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Human Infection Plasmablasts Neuraminidase Monoclonal antibodies Influenza B virus B cells |
| Language | English |
| License | Copyright © 2020 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c557t-dcd02b1f66152804ca045cede6570409f4fb5915d7371dad2f6779a7a43f0e153 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 A.M., Y.D., M.M., A.J.S., J.T., T.L., W.A.B., S.S., M.A., B.M.M., and V.S. characterized the antibodies; A.J.S., J.S.T., and P.A.M. isolated the antibodies; and A.M., Y.D., R.J.C., D.H.F., F.K., and A.H.E. conceptualized the study and wrote the manuscript. AUTHOR CONTRIBUTIONS |
| ORCID | 0000-0003-1618-3043 0000-0002-3860-5473 0000-0002-0626-5443 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/7572813 |
| PMID | 32976769 |
| PQID | 2450755519 |
| PQPubID | 2031079 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7572813 proquest_miscellaneous_2446671778 proquest_journals_2450755519 pubmed_primary_32976769 crossref_primary_10_1016_j_immuni_2020_08_015 crossref_citationtrail_10_1016_j_immuni_2020_08_015 elsevier_sciencedirect_doi_10_1016_j_immuni_2020_08_015 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-13 |
| PublicationDateYYYYMMDD | 2020-10-13 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Cambridge |
| PublicationTitle | Immunity (Cambridge, Mass.) |
| PublicationTitleAlternate | Immunity |
| PublicationYear | 2020 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Taylor, von Itzstein (bib50) 1994; 37 Rota, Wallis, Harmon, Rota, Kendal, Nerome (bib41) 1990; 175 Sato, Saito, Sato, Tanabe, Shobugawa, Sasaki, Li, Suzuki, Sato, Sakai (bib42) 2008; 214 Chong, Pegg, Taylor, von Itzstein (bib8) 1992; 207 Sievers, Higgins (bib43) 2014; 1079 Adams, Afonine, Bunkóczi, Chen, Davis, Echols, Headd, Hung, Kapral, Grosse-Kunstleve (bib1) 2010; 66 Burmeister, Henrissat, Bosso, Cusack, Ruigrok (bib3) 1993; 1 Goddard, Huang, Meng, Pettersen, Couch, Morris, Ferrin (bib20) 2018; 27 Lentz, Webster, Air (bib31) 1987; 26 Stadlbauer, Amanat, Strohmeier, Nachbagauer, Krammer (bib45) 2018; 7 Chen, Arendall, Headd, Keedy, Immormino, Kapral, Murray, Richardson, Richardson (bib5) 2010; 66 Ison, Gubareva, Atmar, Treanor, Hayden (bib25) 2006; 193 Burnham, Baranovich, Govorkova (bib4) 2013; 100 Giudicelli, Brochet, Lefranc (bib19) 2011; 2011 Gubareva, Matrosovich, Brenner, Bethell, Webster (bib22) 1998; 178 Margine, Palese, Krammer (bib32) 2013; 6 Emsley, Cowtan (bib16) 2004; 60 Ellebedy, Webby (bib13) 2009; 27 Zheng, Palovcak, Armache, Verba, Cheng, Agard (bib60) 2017; 14 Hayward, Berendsen (bib23) 1998; 30 Wagner, Merino, Stabrin, Moriya, Antoni, Apelbaum, Hagel, Sitsel, Raisch, Prumbaum (bib52) 2019; 2 Virk, Jayakumar, Mendenhall, Moorthy, Lam, Linster, Lim, Lin, Oon, Lee (bib51) 2020; 117 Tan, Asthagiri Arunkumar, Krammer (bib49) 2018; 53 Mishin, Patel, Chesnokov, De La Cruz, Nguyen, Lollis, Hodges, Jang, Barnes, Uyeki (bib34) 2019; 25 Piepenbrink, Nogales, Basu, Fucile, Liesveld, Keefer, Rosenberg, Martinez-Sobrido, Kobie (bib40) 2019; 10 Zhu, Turner, Lang, McBride, Bangaru, Gilchuk, Yu, Paulson, Crowe, Ward, Wilson (bib61) 2019; 26 Paul Glezen, Schmier, Kuehn, Ryan, Oxford (bib36) 2013; 103 Murin, Wilson, Ward (bib35) 2019; 4 Pettersen, Goddard, Huang, Couch, Greenblatt, Meng, Ferrin (bib39) 2004; 25 Chen, McMullan, Faruqi, Murshudov, Short, Scheres, Henderson (bib6) 2013; 135 Ellebedy, Jackson, Kissick, Nakaya, Davis, Roskin, McElroy, Oshansky, Elbein, Thomas (bib14) 2016; 17 Kawai, Ikematsu, Iwaki, Maeda, Satoh, Hirotsu, Kashiwagi (bib26) 2006; 43 Sugaya, Mitamura, Yamazaki, Tamura, Ichikawa, Kimura, Kawakami, Kiso, Ito, Hatakeyama, Kawaoka (bib47) 2007; 44 Zivanov, Nakane, Forsberg, Kimanius, Hagen, Lindahl, Scheres (bib62) 2018; 7 Wu, Wilson (bib57) 2018; 25 Gilchuk, Bangaru, Gilchuk, Irving, Kose, Bombardi, Thornburg, Creech, Edwards, Li (bib18) 2019; 26 Eichelberger, Morens, Taubenberger (bib11) 2018; 53 Krammer (bib27) 2019; 19 Brochet, Lefranc, Giudicelli (bib2) 2008; 36 Tamura, Stecher, Peterson, Filipski, Kumar (bib48) 2013; 30 Kucukelbir, Sigworth, Tagare (bib29) 2014; 11 Smith, Garman, Wrammert, Zheng, Capra, Ahmed, Wilson (bib44) 2009; 4 Ho, Bunker, Erickson, Neu, Huang, Cortese, Pulendran, Wilson (bib24) 2016; 438 Paules, Marston, Eisinger, Baltimore, Fauci (bib37) 2017; 47 Erbelding, Post, Stemmy, Roberts, Augustine, Ferguson, Paules, Graham, Fauci (bib17) 2018; 218 Wohlbold, Podolsky, Chromikova, Kirkpatrick, Falconieri, Meade, Amanat, Tan, tenOever, Tan (bib55) 2017; 2 DiLillo, Tan, Palese, Ravetch (bib10) 2014; 20 Langat, Raghwani, Dudas, Bowden, Edwards, Gall, Bedford, Rambaut, Daniels, Russell (bib30) 2017; 13 Chen, Wohlbold, Zheng, Huang, Huang, Neu, Lee, Wan, Rojas, Kirkpatrick (bib7) 2018; 173 Ellebedy, Nachbagauer, Jackson, Dai, Han, Alsoussi, Davis, Stadlbauer, Rouphael, Chromikova (bib15) 2020; 117 McMahon, Kirkpatrick, Stadlbauer, Strohmeier, Bouvier, Krammer (bib33) 2019; 10 Ellebedy, Ahmed (bib12) 2012; 3 Krammer, Fouchier, Eichelberger, Webby, Shaw-Saliba, Wan, Wilson, Compans, Skountzou, Monto (bib28) 2018; 9 Wohlbold, Nachbagauer, Xu, Tan, Hirsh, Brokstad, Cox, Palese, Krammer (bib54) 2015; 6 Wrammert, Koutsonanos, Li, Edupuganti, Sui, Morrissey, McCausland, Skountzou, Hornig, Lipkin (bib56) 2011; 208 Paules, Sullivan, Subbarao, Fauci (bib38) 2018; 378 Zhang (bib59) 2016; 193 Crowe (bib9) 2017; 22 Stadlbauer, Zhu, McMahon, Turner, Wohlbold, Schmitz, Strohmeier, Yu, Nachbagauer, Mudd (bib46) 2019; 366 Govorkova, McCullers (bib21) 2013; 370 Xu, Zhu, Dwek, Stevens, Wilson (bib58) 2008; 82 Wilson, Andrews (bib53) 2012; 12 Ellebedy (10.1016/j.immuni.2020.08.015_bib14) 2016; 17 Lentz (10.1016/j.immuni.2020.08.015_bib31) 1987; 26 Krammer (10.1016/j.immuni.2020.08.015_bib28) 2018; 9 Paules (10.1016/j.immuni.2020.08.015_bib37) 2017; 47 Stadlbauer (10.1016/j.immuni.2020.08.015_bib45) 2018; 7 Gilchuk (10.1016/j.immuni.2020.08.015_bib18) 2019; 26 Zivanov (10.1016/j.immuni.2020.08.015_bib62) 2018; 7 Sato (10.1016/j.immuni.2020.08.015_bib42) 2008; 214 Chen (10.1016/j.immuni.2020.08.015_bib7) 2018; 173 Zhu (10.1016/j.immuni.2020.08.015_bib61) 2019; 26 Krammer (10.1016/j.immuni.2020.08.015_bib27) 2019; 19 Pettersen (10.1016/j.immuni.2020.08.015_bib39) 2004; 25 Rota (10.1016/j.immuni.2020.08.015_bib41) 1990; 175 Sugaya (10.1016/j.immuni.2020.08.015_bib47) 2007; 44 Govorkova (10.1016/j.immuni.2020.08.015_bib21) 2013; 370 Langat (10.1016/j.immuni.2020.08.015_bib30) 2017; 13 Eichelberger (10.1016/j.immuni.2020.08.015_bib11) 2018; 53 Ellebedy (10.1016/j.immuni.2020.08.015_bib12) 2012; 3 Ellebedy (10.1016/j.immuni.2020.08.015_bib13) 2009; 27 Wagner (10.1016/j.immuni.2020.08.015_bib52) 2019; 2 Ison (10.1016/j.immuni.2020.08.015_bib25) 2006; 193 Kucukelbir (10.1016/j.immuni.2020.08.015_bib29) 2014; 11 Zheng (10.1016/j.immuni.2020.08.015_bib60) 2017; 14 Giudicelli (10.1016/j.immuni.2020.08.015_bib19) 2011; 2011 Paules (10.1016/j.immuni.2020.08.015_bib38) 2018; 378 Emsley (10.1016/j.immuni.2020.08.015_bib16) 2004; 60 Burmeister (10.1016/j.immuni.2020.08.015_bib3) 1993; 1 Wohlbold (10.1016/j.immuni.2020.08.015_bib55) 2017; 2 Gubareva (10.1016/j.immuni.2020.08.015_bib22) 1998; 178 Piepenbrink (10.1016/j.immuni.2020.08.015_bib40) 2019; 10 Tamura (10.1016/j.immuni.2020.08.015_bib48) 2013; 30 Stadlbauer (10.1016/j.immuni.2020.08.015_bib46) 2019; 366 Smith (10.1016/j.immuni.2020.08.015_bib44) 2009; 4 Ho (10.1016/j.immuni.2020.08.015_bib24) 2016; 438 Zhang (10.1016/j.immuni.2020.08.015_bib59) 2016; 193 Wilson (10.1016/j.immuni.2020.08.015_bib53) 2012; 12 Mishin (10.1016/j.immuni.2020.08.015_bib34) 2019; 25 Erbelding (10.1016/j.immuni.2020.08.015_bib17) 2018; 218 Taylor (10.1016/j.immuni.2020.08.015_bib50) 1994; 37 Adams (10.1016/j.immuni.2020.08.015_bib1) 2010; 66 Xu (10.1016/j.immuni.2020.08.015_bib58) 2008; 82 Chen (10.1016/j.immuni.2020.08.015_bib6) 2013; 135 Hayward (10.1016/j.immuni.2020.08.015_bib23) 1998; 30 Brochet (10.1016/j.immuni.2020.08.015_bib2) 2008; 36 Paul Glezen (10.1016/j.immuni.2020.08.015_bib36) 2013; 103 Goddard (10.1016/j.immuni.2020.08.015_bib20) 2018; 27 Crowe (10.1016/j.immuni.2020.08.015_bib9) 2017; 22 Margine (10.1016/j.immuni.2020.08.015_bib32) 2013; 6 McMahon (10.1016/j.immuni.2020.08.015_bib33) 2019; 10 Chong (10.1016/j.immuni.2020.08.015_bib8) 1992; 207 Wu (10.1016/j.immuni.2020.08.015_bib57) 2018; 25 Ellebedy (10.1016/j.immuni.2020.08.015_bib15) 2020; 117 Virk (10.1016/j.immuni.2020.08.015_bib51) 2020; 117 DiLillo (10.1016/j.immuni.2020.08.015_bib10) 2014; 20 Murin (10.1016/j.immuni.2020.08.015_bib35) 2019; 4 Sievers (10.1016/j.immuni.2020.08.015_bib43) 2014; 1079 Wrammert (10.1016/j.immuni.2020.08.015_bib56) 2011; 208 Burnham (10.1016/j.immuni.2020.08.015_bib4) 2013; 100 Wohlbold (10.1016/j.immuni.2020.08.015_bib54) 2015; 6 Chen (10.1016/j.immuni.2020.08.015_bib5) 2010; 66 Kawai (10.1016/j.immuni.2020.08.015_bib26) 2006; 43 Tan (10.1016/j.immuni.2020.08.015_bib49) 2018; 53 33446888 - Cell Mol Immunol. 2021 Jul;18(7):1615-1617 33158977 - Sci Immunol. 2020 Nov 6;5(53) |
| References_xml | – volume: 2011 start-page: 695 year: 2011 end-page: 715 ident: bib19 article-title: IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences publication-title: Cold Spring Harb. Protoc. – volume: 1079 start-page: 105 year: 2014 end-page: 116 ident: bib43 article-title: Clustal Omega, accurate alignment of very large numbers of sequences publication-title: Methods Mol. Biol. – volume: 30 start-page: 2725 year: 2013 end-page: 2729 ident: bib48 article-title: MEGA6: Molecular Evolutionary Genetics Analysis version 6.0 publication-title: Mol. Biol. Evol. – volume: 66 start-page: 12 year: 2010 end-page: 21 ident: bib5 article-title: MolProbity: all-atom structure validation for macromolecular crystallography publication-title: Acta Crystallogr. D Biol. Crystallogr. – volume: 19 start-page: 383 year: 2019 end-page: 397 ident: bib27 article-title: The human antibody response to influenza A virus infection and vaccination publication-title: Nat. Rev. Immunol. – volume: 13 start-page: e1006749 year: 2017 ident: bib30 article-title: Genome-wide evolutionary dynamics of influenza B viruses on a global scale publication-title: PLoS Pathog. – volume: 25 start-page: 115 year: 2018 end-page: 121 ident: bib57 article-title: Structural insights into the design of novel anti-influenza therapies publication-title: Nat. Struct. Mol. Biol. – volume: 25 start-page: 1969 year: 2019 end-page: 1972 ident: bib34 article-title: Susceptibility of influenza A, B, C, and D viruses to baloxavir1 publication-title: Emerg. Infect. Dis. – volume: 22 start-page: 193 year: 2017 end-page: 206 ident: bib9 article-title: Principles of broad and potent antiviral human antibodies: insights for vaccine design publication-title: Cell Host Microbe – volume: 193 start-page: 1 year: 2016 end-page: 12 ident: bib59 article-title: Gctf: Real-time CTF determination and correction publication-title: J. Struct. Biol. – volume: 178 start-page: 1257 year: 1998 end-page: 1262 ident: bib22 article-title: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus publication-title: J. Infect. Dis. – volume: 26 start-page: 5351 year: 1987 end-page: 5358 ident: bib31 article-title: Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism publication-title: Biochemistry – volume: 207 start-page: 335 year: 1992 end-page: 343 ident: bib8 article-title: Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus publication-title: Eur. J. Biochem. – volume: 117 start-page: 619 year: 2020 end-page: 628 ident: bib51 article-title: Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity publication-title: Proc. Natl. Acad. Sci. USA – volume: 36 start-page: W503 year: 2008 end-page: W508 ident: bib2 article-title: IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis publication-title: Nucleic Acids Res. – volume: 12 start-page: 709 year: 2012 end-page: 719 ident: bib53 article-title: Tools to therapeutically harness the human antibody response publication-title: Nat. Rev. Immunol. – volume: 20 start-page: 143 year: 2014 end-page: 151 ident: bib10 article-title: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo publication-title: Nat. Med. – volume: 370 start-page: 273 year: 2013 end-page: 300 ident: bib21 article-title: Therapeutics against influenza publication-title: Curr. Top. Microbiol. Immunol. – volume: 10 year: 2019 ident: bib40 article-title: Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells publication-title: MBio – volume: 53 start-page: 38 year: 2018 end-page: 44 ident: bib11 article-title: Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness publication-title: Curr. Opin. Immunol. – volume: 3 start-page: 53 year: 2012 ident: bib12 article-title: Re-engaging cross-reactive memory B cells: the influenza puzzle publication-title: Front. Immunol. – volume: 214 start-page: 113 year: 2008 end-page: 120 ident: bib42 article-title: Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan publication-title: Tohoku J. Exp. Med. – volume: 103 start-page: e43 year: 2013 end-page: e51 ident: bib36 article-title: The burden of influenza B: a structured literature review publication-title: Am. J. Public Health – volume: 1 start-page: 19 year: 1993 end-page: 26 ident: bib3 article-title: Influenza B virus neuraminidase can synthesize its own inhibitor publication-title: Structure – volume: 4 start-page: 372 year: 2009 end-page: 384 ident: bib44 article-title: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen publication-title: Nat. Protoc. – volume: 193 start-page: 760 year: 2006 end-page: 764 ident: bib25 article-title: Recovery of drug-resistant influenza virus from immunocompromised patients: a case series publication-title: J. Infect. Dis. – volume: 4 start-page: 734 year: 2019 end-page: 747 ident: bib35 article-title: Antibody responses to viral infections: a structural perspective across three different enveloped viruses publication-title: Nat. Microbiol. – volume: 117 start-page: 17957 year: 2020 end-page: 17964 ident: bib15 article-title: Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans publication-title: Proc. Natl. Acad. Sci. USA – volume: 173 start-page: 417 year: 2018 end-page: 429.e10 ident: bib7 article-title: Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies publication-title: Cell – volume: 7 year: 2018 ident: bib62 article-title: New tools for automated high-resolution cryo-EM structure determination in RELION-3 publication-title: eLife – volume: 26 start-page: 715 year: 2019 end-page: 728.e8 ident: bib18 article-title: Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice publication-title: Cell Host Microbe – volume: 6 start-page: e02556 year: 2015 ident: bib54 article-title: Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice publication-title: MBio – volume: 30 start-page: 144 year: 1998 end-page: 154 ident: bib23 article-title: Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme publication-title: Proteins – volume: 53 start-page: 45 year: 2018 end-page: 50 ident: bib49 article-title: Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? publication-title: Curr. Opin. Immunol. – volume: 218 start-page: 347 year: 2018 end-page: 354 ident: bib17 article-title: A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases publication-title: J. Infect. Dis. – volume: 9 year: 2018 ident: bib28 article-title: NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? publication-title: MBio – volume: 6 start-page: e51112 year: 2013 ident: bib32 article-title: Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system publication-title: J. Vis. Exp. – volume: 135 start-page: 24 year: 2013 end-page: 35 ident: bib6 article-title: High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy publication-title: Ultramicroscopy – volume: 438 start-page: 67 year: 2016 end-page: 70 ident: bib24 article-title: Refined protocol for generating monoclonal antibodies from single human and murine B cells publication-title: J. Immunol. Methods – volume: 26 start-page: 729 year: 2019 end-page: 738.e4 ident: bib61 article-title: Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies publication-title: Cell Host Microbe – volume: 17 start-page: 1226 year: 2016 end-page: 1234 ident: bib14 article-title: Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination publication-title: Nat. Immunol. – volume: 66 start-page: 213 year: 2010 end-page: 221 ident: bib1 article-title: PHENIX: a comprehensive Python-based system for macromolecular structure solution publication-title: Acta Crystallogr. D Biol. Crystallogr. – volume: 7 start-page: 110 year: 2018 ident: bib45 article-title: Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model publication-title: Emerg. Microbes Infect. – volume: 10 year: 2019 ident: bib33 article-title: Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs publication-title: MBio – volume: 27 start-page: D65 year: 2009 end-page: D68 ident: bib13 article-title: Influenza vaccines publication-title: Vaccine – volume: 43 start-page: 439 year: 2006 end-page: 444 ident: bib26 article-title: A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons publication-title: Clin. Infect. Dis. – volume: 2 start-page: 1415 year: 2017 end-page: 1424 ident: bib55 article-title: Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes publication-title: Nat. Microbiol. – volume: 25 start-page: 1605 year: 2004 end-page: 1612 ident: bib39 article-title: UCSF Chimera--a visualization system for exploratory research and analysis publication-title: J. Comput. Chem. – volume: 208 start-page: 181 year: 2011 end-page: 193 ident: bib56 article-title: Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection publication-title: J. Exp. Med. – volume: 100 start-page: 520 year: 2013 end-page: 534 ident: bib4 article-title: Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance publication-title: Antiviral Res. – volume: 60 start-page: 2126 year: 2004 end-page: 2132 ident: bib16 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D Biol. Crystallogr. – volume: 2 start-page: 218 year: 2019 ident: bib52 article-title: SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM publication-title: Commun Biol – volume: 47 start-page: 599 year: 2017 end-page: 603 ident: bib37 article-title: The pathway to a universal influenza vaccine publication-title: Immunity – volume: 44 start-page: 197 year: 2007 end-page: 202 ident: bib47 article-title: Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children publication-title: Clin. Infect. Dis. – volume: 27 start-page: 14 year: 2018 end-page: 25 ident: bib20 article-title: UCSF ChimeraX: Meeting modern challenges in visualization and analysis publication-title: Protein Sci. – volume: 366 start-page: 499 year: 2019 end-page: 504 ident: bib46 article-title: Broadly protective human antibodies that target the active site of influenza virus neuraminidase publication-title: Science – volume: 82 start-page: 10493 year: 2008 end-page: 10501 ident: bib58 article-title: Structural characterization of the 1918 influenza virus H1N1 neuraminidase publication-title: J. Virol. – volume: 175 start-page: 59 year: 1990 end-page: 68 ident: bib41 article-title: Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983 publication-title: Virology – volume: 378 start-page: 7 year: 2018 end-page: 9 ident: bib38 article-title: Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine publication-title: N. Engl. J. Med. – volume: 14 start-page: 331 year: 2017 end-page: 332 ident: bib60 article-title: MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy publication-title: Nat. Methods – volume: 11 start-page: 63 year: 2014 end-page: 65 ident: bib29 article-title: Quantifying the local resolution of cryo-EM density maps publication-title: Nat. Methods – volume: 37 start-page: 616 year: 1994 end-page: 624 ident: bib50 article-title: Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis publication-title: J. Med. Chem. – volume: 37 start-page: 616 year: 1994 ident: 10.1016/j.immuni.2020.08.015_bib50 article-title: Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis publication-title: J. Med. Chem. doi: 10.1021/jm00031a011 – volume: 2011 start-page: 695 year: 2011 ident: 10.1016/j.immuni.2020.08.015_bib19 article-title: IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences publication-title: Cold Spring Harb. Protoc. – volume: 26 start-page: 5351 year: 1987 ident: 10.1016/j.immuni.2020.08.015_bib31 article-title: Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism publication-title: Biochemistry doi: 10.1021/bi00391a020 – volume: 117 start-page: 619 year: 2020 ident: 10.1016/j.immuni.2020.08.015_bib51 article-title: Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1916585116 – volume: 66 start-page: 213 year: 2010 ident: 10.1016/j.immuni.2020.08.015_bib1 article-title: PHENIX: a comprehensive Python-based system for macromolecular structure solution publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444909052925 – volume: 27 start-page: 14 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib20 article-title: UCSF ChimeraX: Meeting modern challenges in visualization and analysis publication-title: Protein Sci. doi: 10.1002/pro.3235 – volume: 22 start-page: 193 year: 2017 ident: 10.1016/j.immuni.2020.08.015_bib9 article-title: Principles of broad and potent antiviral human antibodies: insights for vaccine design publication-title: Cell Host Microbe doi: 10.1016/j.chom.2017.07.013 – volume: 135 start-page: 24 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib6 article-title: High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy publication-title: Ultramicroscopy doi: 10.1016/j.ultramic.2013.06.004 – volume: 30 start-page: 144 year: 1998 ident: 10.1016/j.immuni.2020.08.015_bib23 article-title: Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme publication-title: Proteins doi: 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N – volume: 26 start-page: 715 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib18 article-title: Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.10.003 – volume: 370 start-page: 273 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib21 article-title: Therapeutics against influenza publication-title: Curr. Top. Microbiol. Immunol. – volume: 117 start-page: 17957 year: 2020 ident: 10.1016/j.immuni.2020.08.015_bib15 article-title: Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1906613117 – volume: 193 start-page: 1 year: 2016 ident: 10.1016/j.immuni.2020.08.015_bib59 article-title: Gctf: Real-time CTF determination and correction publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2015.11.003 – volume: 25 start-page: 115 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib57 article-title: Structural insights into the design of novel anti-influenza therapies publication-title: Nat. Struct. Mol. Biol. doi: 10.1038/s41594-018-0025-9 – volume: 207 start-page: 335 year: 1992 ident: 10.1016/j.immuni.2020.08.015_bib8 article-title: Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus publication-title: Eur. J. Biochem. doi: 10.1111/j.1432-1033.1992.tb17055.x – volume: 378 start-page: 7 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib38 article-title: Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine publication-title: N. Engl. J. Med. doi: 10.1056/NEJMp1714916 – volume: 7 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib62 article-title: New tools for automated high-resolution cryo-EM structure determination in RELION-3 publication-title: eLife doi: 10.7554/eLife.42166 – volume: 6 start-page: e51112 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib32 article-title: Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system publication-title: J. Vis. Exp. – volume: 53 start-page: 38 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib11 article-title: Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2018.03.025 – volume: 11 start-page: 63 year: 2014 ident: 10.1016/j.immuni.2020.08.015_bib29 article-title: Quantifying the local resolution of cryo-EM density maps publication-title: Nat. Methods doi: 10.1038/nmeth.2727 – volume: 10 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib33 article-title: Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs publication-title: MBio doi: 10.1128/mBio.00560-19 – volume: 10 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib40 article-title: Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells publication-title: MBio doi: 10.1128/mBio.00066-19 – volume: 2 start-page: 1415 year: 2017 ident: 10.1016/j.immuni.2020.08.015_bib55 article-title: Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes publication-title: Nat. Microbiol. doi: 10.1038/s41564-017-0011-8 – volume: 17 start-page: 1226 year: 2016 ident: 10.1016/j.immuni.2020.08.015_bib14 article-title: Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination publication-title: Nat. Immunol. doi: 10.1038/ni.3533 – volume: 438 start-page: 67 year: 2016 ident: 10.1016/j.immuni.2020.08.015_bib24 article-title: Refined protocol for generating monoclonal antibodies from single human and murine B cells publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2016.09.001 – volume: 20 start-page: 143 year: 2014 ident: 10.1016/j.immuni.2020.08.015_bib10 article-title: Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo publication-title: Nat. Med. doi: 10.1038/nm.3443 – volume: 43 start-page: 439 year: 2006 ident: 10.1016/j.immuni.2020.08.015_bib26 article-title: A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons publication-title: Clin. Infect. Dis. doi: 10.1086/505868 – volume: 9 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib28 article-title: NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? publication-title: MBio doi: 10.1128/mBio.02332-17 – volume: 3 start-page: 53 year: 2012 ident: 10.1016/j.immuni.2020.08.015_bib12 article-title: Re-engaging cross-reactive memory B cells: the influenza puzzle publication-title: Front. Immunol. doi: 10.3389/fimmu.2012.00053 – volume: 6 start-page: e02556 year: 2015 ident: 10.1016/j.immuni.2020.08.015_bib54 article-title: Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice publication-title: MBio doi: 10.1128/mBio.02556-14 – volume: 103 start-page: e43 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib36 article-title: The burden of influenza B: a structured literature review publication-title: Am. J. Public Health doi: 10.2105/AJPH.2012.301137 – volume: 44 start-page: 197 year: 2007 ident: 10.1016/j.immuni.2020.08.015_bib47 article-title: Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children publication-title: Clin. Infect. Dis. doi: 10.1086/509925 – volume: 366 start-page: 499 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib46 article-title: Broadly protective human antibodies that target the active site of influenza virus neuraminidase publication-title: Science doi: 10.1126/science.aay0678 – volume: 208 start-page: 181 year: 2011 ident: 10.1016/j.immuni.2020.08.015_bib56 article-title: Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection publication-title: J. Exp. Med. doi: 10.1084/jem.20101352 – volume: 25 start-page: 1969 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib34 article-title: Susceptibility of influenza A, B, C, and D viruses to baloxavir1 publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2510.190607 – volume: 4 start-page: 734 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib35 article-title: Antibody responses to viral infections: a structural perspective across three different enveloped viruses publication-title: Nat. Microbiol. doi: 10.1038/s41564-019-0392-y – volume: 36 start-page: W503 year: 2008 ident: 10.1016/j.immuni.2020.08.015_bib2 article-title: IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis publication-title: Nucleic Acids Res. doi: 10.1093/nar/gkn316 – volume: 30 start-page: 2725 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib48 article-title: MEGA6: Molecular Evolutionary Genetics Analysis version 6.0 publication-title: Mol. Biol. Evol. doi: 10.1093/molbev/mst197 – volume: 100 start-page: 520 year: 2013 ident: 10.1016/j.immuni.2020.08.015_bib4 article-title: Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2013.08.023 – volume: 178 start-page: 1257 year: 1998 ident: 10.1016/j.immuni.2020.08.015_bib22 article-title: Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus publication-title: J. Infect. Dis. doi: 10.1086/314440 – volume: 13 start-page: e1006749 year: 2017 ident: 10.1016/j.immuni.2020.08.015_bib30 article-title: Genome-wide evolutionary dynamics of influenza B viruses on a global scale publication-title: PLoS Pathog. doi: 10.1371/journal.ppat.1006749 – volume: 173 start-page: 417 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib7 article-title: Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies publication-title: Cell doi: 10.1016/j.cell.2018.03.030 – volume: 1079 start-page: 105 year: 2014 ident: 10.1016/j.immuni.2020.08.015_bib43 article-title: Clustal Omega, accurate alignment of very large numbers of sequences publication-title: Methods Mol. Biol. doi: 10.1007/978-1-62703-646-7_6 – volume: 47 start-page: 599 year: 2017 ident: 10.1016/j.immuni.2020.08.015_bib37 article-title: The pathway to a universal influenza vaccine publication-title: Immunity doi: 10.1016/j.immuni.2017.09.007 – volume: 82 start-page: 10493 year: 2008 ident: 10.1016/j.immuni.2020.08.015_bib58 article-title: Structural characterization of the 1918 influenza virus H1N1 neuraminidase publication-title: J. Virol. doi: 10.1128/JVI.00959-08 – volume: 193 start-page: 760 year: 2006 ident: 10.1016/j.immuni.2020.08.015_bib25 article-title: Recovery of drug-resistant influenza virus from immunocompromised patients: a case series publication-title: J. Infect. Dis. doi: 10.1086/500465 – volume: 27 start-page: D65 issue: Suppl 4 year: 2009 ident: 10.1016/j.immuni.2020.08.015_bib13 article-title: Influenza vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2009.08.038 – volume: 60 start-page: 2126 year: 2004 ident: 10.1016/j.immuni.2020.08.015_bib16 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444904019158 – volume: 7 start-page: 110 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib45 article-title: Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model publication-title: Emerg. Microbes Infect. doi: 10.1038/s41426-018-0115-0 – volume: 66 start-page: 12 year: 2010 ident: 10.1016/j.immuni.2020.08.015_bib5 article-title: MolProbity: all-atom structure validation for macromolecular crystallography publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444909042073 – volume: 2 start-page: 218 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib52 article-title: SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM publication-title: Commun Biol doi: 10.1038/s42003-019-0437-z – volume: 12 start-page: 709 year: 2012 ident: 10.1016/j.immuni.2020.08.015_bib53 article-title: Tools to therapeutically harness the human antibody response publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3285 – volume: 14 start-page: 331 year: 2017 ident: 10.1016/j.immuni.2020.08.015_bib60 article-title: MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy publication-title: Nat. Methods doi: 10.1038/nmeth.4193 – volume: 214 start-page: 113 year: 2008 ident: 10.1016/j.immuni.2020.08.015_bib42 article-title: Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan publication-title: Tohoku J. Exp. Med. doi: 10.1620/tjem.214.113 – volume: 175 start-page: 59 year: 1990 ident: 10.1016/j.immuni.2020.08.015_bib41 article-title: Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983 publication-title: Virology doi: 10.1016/0042-6822(90)90186-U – volume: 218 start-page: 347 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib17 article-title: A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiy103 – volume: 53 start-page: 45 year: 2018 ident: 10.1016/j.immuni.2020.08.015_bib49 article-title: Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2018.04.002 – volume: 26 start-page: 729 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib61 article-title: Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies publication-title: Cell Host Microbe doi: 10.1016/j.chom.2019.10.002 – volume: 4 start-page: 372 year: 2009 ident: 10.1016/j.immuni.2020.08.015_bib44 article-title: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen publication-title: Nat. Protoc. doi: 10.1038/nprot.2009.3 – volume: 25 start-page: 1605 year: 2004 ident: 10.1016/j.immuni.2020.08.015_bib39 article-title: UCSF Chimera--a visualization system for exploratory research and analysis publication-title: J. Comput. Chem. doi: 10.1002/jcc.20084 – volume: 1 start-page: 19 year: 1993 ident: 10.1016/j.immuni.2020.08.015_bib3 article-title: Influenza B virus neuraminidase can synthesize its own inhibitor publication-title: Structure doi: 10.1016/0969-2126(93)90005-2 – volume: 19 start-page: 383 year: 2019 ident: 10.1016/j.immuni.2020.08.015_bib27 article-title: The human antibody response to influenza A virus infection and vaccination publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0143-6 – reference: 33158977 - Sci Immunol. 2020 Nov 6;5(53): – reference: 33446888 - Cell Mol Immunol. 2021 Jul;18(7):1615-1617 |
| SSID | ssj0014590 |
| Score | 2.5495958 |
| Snippet | Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV... SummaryInfluenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 852 |
| SubjectTerms | Animals Antibodies Antibodies, Monoclonal - immunology Antibodies, Viral - immunology Antiviral agents Antiviral drugs B cells Catalytic Domain - immunology Cell Line Dogs Drug dosages Enzymatic activity Enzymes Exo-a-sialidase Female HEK293 Cells Human Humans Infection Infections Influenza Influenza A Influenza A virus - immunology Influenza B Influenza B virus Influenza B virus - immunology Influenza, Human - immunology Leukocytes, Mononuclear - immunology Madin Darby Canine Kidney Cells Mice Mice, Inbred BALB C Middle Aged Monoclonal antibodies Neuraminidase Neuraminidase - immunology Orthomyxoviridae Infections - immunology Plasmablasts Proteins Vaccines Viral Proteins - immunology Viruses |
| Title | Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective |
| URI | https://dx.doi.org/10.1016/j.immuni.2020.08.015 https://www.ncbi.nlm.nih.gov/pubmed/32976769 https://www.proquest.com/docview/2450755519 https://www.proquest.com/docview/2446671778 https://pubmed.ncbi.nlm.nih.gov/PMC7572813 |
| Volume | 53 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSxxBEC5EMeQSEk3iJkY64HXY6ffMcRXFKIYQH9lLaHpmunFEZkV3D-bXp7rnQdYIgsfd7mZn-1H11fRXXwHs-gx9slNFgr7eJYJRkeTxll3alJVBsb0MCc6n39XRhTieyukK7Pe5MIFW2dn-1qZHa919M-5mc3xb1-OzQCXEIJwz3Kdcx2RyLrKYxDfdG24ShMzTgXeIvfv0ucjxqmMOBkaJLI1CnqE47tPu6X_4-ZhF-Y9bOnwLbzo8SSbtI7-DFddswHpbYfJhA16ddnfnm_A7vq8nk2ZeF7PAHSTnkQWOvot8a0uV_LFkj1zWd4t7EkQ7bNAdqdDNkUm0iuQM8Sn-lCMYvNvq5oH8aFUesO09XBwenO8fJV1xhaSUUs-TqqxSVlCP_lmyLBWlRXCHk-4CFwaDPi98IXMqK801rWzFvNI6t9oK7lOHdvIDrDazxm0BoQxBoaVKOeWFpVWRM18KVXpmJVoMPgLez6kpO-XxUADjxvQUs2vTroQJK2FCXUwqR5AMo25b5Y1n-ut-uczSDjLoHJ4Zud2vrulO8L1hApGyRDyZj-Dr0IxnL1yo2MbNFqGPUArjYZ2N4GO7GYZH5QyBnlY4Wi9tk6FD0PVebmnqq6jvraVmGeWfXvyHPsPr8Cm4WMq3YXV-t3BfEDvNix1Ym5z8_HWyEw_JX4KXGN8 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VRTwuCAqUhQJGgmPU2LHjzYHDLlDt0m6F1C3aCzJO4oigKlvtQ2j5W_xBZpyHWECqhNRrbCuJZzzzjebzDMCroo8-2cVpgL7eBVJwGSQ-y65sKDKq2J7RBefJaTw6lx9marYDP9u7MESrbGx_bdO9tW6eHDa7eXhZlodnRCXEIDwSqKcRBjINs_LYbb5j3LZ8M36HQn4txNH76dtR0LQWCDKl9CrIszwUKS_QOynRD2VmEdrgKx0xQTDkKWSRqoSrXEea5zYXRax1YrWVURE6Tq0i0O7fQPShyRqMZ8MudSFVEnZER_y89r6eJ5WV_tIHhqUi9JVDqRvvv_3h33j3T9rmb37w6B7cbQAsG9R7dB92XLUHN-uWlps9uDVpkvUP4LNPELBBtSrTOZEV2dTTztFZsnHdG-WHZUP2qVysl4yqhFgqdJKjX2UDb4bZGQJifJVjw8Xc5hcb9rEuK4FjD-H8Wrb8EexW88o9BsYFolDL49jFhbQ8TxNRZDLOCmEVmqioB1G7pyZrSp1Tx40L03LavplaEoYkYagRJ1c9CLpVl3Wpjyvm61ZcZktlDXqjK1YetNI1jclYGiERmisEsEkPXnbDeNgpg2MrN1_THBmjxmnd78F-rQzdp0YCkaWOcbXeUpNuAhUS3x6pyq--oLhWWvR59OS_f-gF3B5NJyfmZHx6_BTu0Aj5dx4dwO5qsXbPELit0uf-oDD4ct0n8xdCjFPQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+Antibodies+Targeting+Influenza+B+Virus+Neuraminidase+Active+Site+Are+Broadly+Protective&rft.jtitle=Immunity+%28Cambridge%2C+Mass.%29&rft.au=Madsen%2C+Anders&rft.au=Dai%2C+Ya-Nan&rft.au=McMahon%2C+Meagan&rft.au=Schmitz%2C+Aaron+J.&rft.date=2020-10-13&rft.pub=Elsevier+Inc&rft.issn=1074-7613&rft.eissn=1097-4180&rft.volume=53&rft.issue=4&rft.spage=852&rft.epage=863.e7&rft_id=info:doi/10.1016%2Fj.immuni.2020.08.015&rft.externalDocID=S1074761320303721 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1074-7613&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1074-7613&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1074-7613&client=summon |